NASDAQ:AUPH - Aurinia Pharmaceuticals Stock Price, Forecast & News

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its quarterly earnings results on Thursday, November, 14th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The biotechnology company earned $0.23 million during the quarter, compared to analysts' expectations of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.79% and a negative net margin of 19,483.96%. View Aurinia Pharmaceuticals' Earnings History.

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Aurinia Pharmaceuticals.

8 Wall Street analysts have issued 12-month price objectives for Aurinia Pharmaceuticals' shares. Their forecasts range from $11.00 to $32.00. On average, they expect Aurinia Pharmaceuticals' share price to reach $22.29 in the next twelve months. This suggests a possible upside of 17.6% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

Media coverage about AUPH stock has trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aurinia Pharmaceuticals earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals saw a decrease in short interest in December. As of December 31st, there was short interest totalling 5,500,000 shares, a decrease of 23.7% from the December 15th total of 7,210,000 shares. Based on an average daily volume of 3,520,000 shares, the days-to-cover ratio is presently 1.6 days. Approximately 6.9% of the shares of the stock are sold short. View Aurinia Pharmaceuticals' Current Options Chain.

Some companies that are related to Aurinia Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Amarin (AMRN), Horizon Therapeutics (HZNP), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Reata Pharmaceuticals (RETA), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), BridgeBio Pharma (BBIO), United Therapeutics (UTHR) and Nektar Therapeutics (NKTR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Array Biopharma (ARRY), Cara Therapeutics (CARA), Micron Technology (MU), Exelixis (EXEL), Novavax (NVAX), Corbus Pharmaceuticals (CRBP) and Synergy Pharmaceuticals (SGYP).

Aurinia Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Patriot Financial Group Insurance Agency LLC (0.00%) and Steward Partners Investment Advisory LLC (0.00%).

AUPH stock was sold by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC.

AUPH stock was bought by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC.

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AUPH stock can currently be purchased for approximately $18.95.

Aurinia Pharmaceuticals has a market capitalization of $2.12 billion and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]